Merck/ALK-Abello plan 2013 US filings for ragweed and grass allergy immunotherapy
This article was originally published in Scrip
Executive Summary
Merck & Co and its partner ALK-Abello plan to file for US approval of their investigational ragweed and grass allergy immunotherapy (AIT) tablets next year, following the announcement of positive Phase III results for the ragweed pollen AIT at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Orlando, Florida.